“Conclusion Imiquimod treatment inhibits OVA induced airway inflammation by modulating key master switches GATA‐3 and T‐bet that result in committing T helper cells to a Th1 phenotype.”
“Results It … demonstrated that imiquimod 1) … OVA induced airway inflammation; 2) diminished the degree of airway hyperresponsiveness (AHR); 3) decreased the Th2 type cytokines and increased Thl type cytokines mRNA and protein levels; 4) modulated the Thl/Th2 reaction by inhibiting GATA‐3 production and increasing T‐bet production.”